Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Nephrology
•
General Infectious Disease
•
Geriatric Medicine
How do you approach the use of Paxlovid in patients with COVID-19 and CKD Stage 4?
CKD Stage 4: eGFR between 15 and 29 mL/min/1.73 m²
Nieves MC, et al., PMID 40204015
Related Questions
Would you avoid using cephalosporins in a patient with a history of cephalosporin neurotoxicity in the setting of CKD?
Do you routinely continue dual antibiotic coverage or de-escalate to monotherapy based on peritoneal fluid culture sensitivities in patients with relapsing pseudomonas aeruginosa peritoneal dialysis peritonitis after peritoneal catheter removal?
For patients with candida species osteomyelitis who have undergone extensive surgical debridement, do you routinely still recommend 6-12 months of antifungal therapy or opt for a shorter duration?
How do you balance the risk of unnecessary treatment with acyclovir against the risk of delaying treatment in encephalitis cases where CSF pleocytosis is absent?
Do you approach suppressive antibiotic therapy differently for patients with cardiac implant- able electronic devices infections compared to patients with LVAD related infections?
In what situations would you treat a corynebacterium positive blood culture as a true pathogen compared to a contaminant?
Do you give chronic antibiotic prophylaxis for recurrent UTIs, including Pseudomonas aeruginosa, in a patient with retained ureteral stents?
Do you routinely recommend an immunodeficiency work up in patients with ARDS due to influenza infection who develop invasive pulmonary aspergillosis?
Are you less likely to use cefiderocol for carbapenem-resistant Gram-negative bloodstream infections based on the GAME CHANGER trial showing non-inferiority to standard-of-care antibiotics?
Do you routinely recommend adjunctive rifampin therapy for the management of Staphylococcus aureus native vertebral osteomyelitis?
